Navigation Links
Misonix Exhibits at Major Worldwide Spine Conference
Date:7/11/2012

FARMINGDALE, N.Y., July 11, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced its participation in SpineWeek 2012, which recently took place in Amsterdam, Netherlands. This is the third meeting in the series, which commenced in 2004.

SpineWeek takes place every four years and synchronizes the annual meetings of leading scientific societies, focused on disorders of the spine, in one location, simplifying logistics while maximizing the exchange of information generated from research and clinical practice. Clinician attendance was greater than 2,600 individuals, including many recognized leaders in the field, who attended from all corners of the globe. 

A key component of SpineWeek, sponsored by the medical device industry, is a major exhibition of innovative products and services used by spine surgeons worldwide. This unique forum provided a showcase for the Company's innovative BoneScalpel™ Ultrasonic Bone Cutting System, including some recent line extensions, and provided an opportunity for more than 100 clinicians in attendance to participate in "hands on" demonstrations of this important new technology. More than 75 of these physicians requested presentations and/or evaluations at their respective hospitals. In addition, multiple existing users of the technology visited the exhibit to share their experiences with clinical use of the Product, commenting on the precise nature of the bone cuts, minimal bone loss, reduced bleeding, reduction in procedure time and a general feeling that BoneScalpel provided an extra measure of safety.

As stated by noted German neurosurgeon, Daniel Rosenthal, "I use the BoneScalpel in arthrectomy or vertebrectomy, and to decompress the foramina. In my opinion, it replaces the saw or drill in spine surgery."

The BoneScalpel is a tissue specific osteotomy device capable of safely making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps. To date, reported uses of the Product in spine surgery include laminectomy, laminotomy, laminoplasty, corpectomy, spinal deformity, foraminotomy, facetectomy and other procedures performed by orthopedic and neuro surgeons.

"We were very pleased to participate in this singular event that brings together researchers and thought leaders from around the globe that specialize in correcting spinal disorders," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Exhibiting our state-of-the-art technology at this prestigious gathering further demonstrates our commitment to providing products to the medical community that can directly impact patient outcomes."

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.Investor Relations ContactsMisonix Contact: 

Lytham Partners, LLCRichard Zaremba

Robert Blum, Joe Dorame, Joe Diaz631-694-9555 

602-889-9700invest@misonix.com 

mson@lythampartners.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix And SIAD Healthcare Renew Distribution Agreement For Italy
2. Misonix Announces New Distribution Agreement For Panama
3. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
4. Cardiosolutions, Inc. Gathers Major Investment from Sorin Group
5. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
6. LIVE VIA SATELLITE: Physician Demonstrates New Medical Technology to Combat Back Pain without Major Surgery
7. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
8. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
9. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
10. NicOx Signs Worldwide Licensing Agreement With Rapid Pathogen Screening, Inc. For Ophthalmic Diagnostics
11. Kansas City Region Launches Contract Research Initiative To Speed The Development Of Health Care Innovation Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ALBANY, New York , April 27, 2016 /PRNewswire/ ... new market report titled, "Skincare Devices Market - Global ... - 2023." According to the report, the global skincare ... 2014 and is anticipated to expand at a CAGR ... 17,299.4 Mn in 2023. Browse the full Skincare ...
(Date:4/27/2016)... , April 27, 2016  Bayer Animal ... a senior from the University of Florida College ... the Bayer Excellence in Communication Award (BECA). Brittany ... which were awarded a total of $70,000 in ... last four years, Bayer has provided a total ...
(Date:4/27/2016)... 2016 Oasmia Pharmaceutical AB ... a new generation of drugs within human and ... for Paclical/Apealea in the Phase III study that ... ovarian cancer. These preliminary results showed non-inferiority between ... carboplatin versus Taxol in combination with carboplatin. In ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... MedPro Waste Disposal, LLC (MedPro) is proud ... now offers its mail back service for an all-inclusive rate. MedPro Disposal President, Dan ... provide service to all of the clients in the country who are looking for ...
(Date:5/2/2016)... ... ... Further establishing itself as a leader in natural pet products category, Paragon ... selected from over 1,000 entrants as a winner and recipient of the prestigious GLOBAL ... dogs are a favorite product among pet-parents worldwide, as each whimsical knobby shape of ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Rassouli, dentist in ... cognitive decline. According to the research, which was published in the “Journal of the ... decline, and about 5.4 million Americans have Alzheimer’s disease. The study found that dental ...
(Date:5/2/2016)... ... ... The 2016 World Ultimate & Guts Championship (WUGC) Mixed roster was announced in February and ... WUGC is being held in London, England this year from June 18-25. At the last ... gold in the women’s masters division, and a silver in the women’s division, so Mazur ...
(Date:5/2/2016)... , ... May 02, 2016 , ... According to an ... one in four girls are sexually abused before the age of 18. Of those ... to tell her story and others. , In her new book, Lyah! Lyah! ...
Breaking Medicine News(10 mins):